DYRK1B-STAT3通过损害线粒体生物能量驱动心脏缩和心脏衰竭
Lingfang Zhuang1,2, Kangni Jia1,2, Chen Chen1,3
1Department of Cardiovascular Medicine (L.Z., K..J., Z.L., J.Z., J.H., H.Z., Q.F., C.H., H.X., L.L., W.S., R.Z., K.C., X.Y.), Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Circulation
|March 2, 2022
概括
双特异性氨酸调节激酶1B (DYRK1B) 通过损害线粒体功能促进心力衰竭. 在心力衰竭模型中,抑制DYRK1B或STAT3可以改善心脏性能和线粒体的生物能量.
科学领域:
- 心脏病学
- 分子生物学
- 线粒体生物学
背景情况:
- 心脏衰竭是全球的主要健康问题.
- 线粒体功能障碍与心力衰竭的进展有关,但机制尚不清楚.
- 激酶可以影响线粒体功能,促使对DYRK1B进行研究.
研究的目的:
- 研究DYRK1B在线粒体生物能学,心脏缩和心力衰竭中的作用.
- 阐明DYRK1B影响心脏功能的机制.
主要方法:
- 工程DYRK1B转基因和淘汰小鼠.
- 用于体内心脏缩模型的横向大动脉收缩.
- 进行RNA测序和线粒体功能分析.
主要成果:
- DYRK1B在衰竭的人类心脏和过度缩的小鼠心脏中得到了上调.
- 过度表达DYRK1B导致心脏功能障碍和纤维化.
- 通过STAT3/PGC-1α途径恢复线粒体的生物能量,DYRK1B的删除减轻了心脏缩和衰竭.
结论:
- DYRK1B在线粒体功能障碍,心脏缩和心力衰竭中起着至关重要的作用.
- 抑制DYRK1B是一种潜在的治疗心力衰竭策略.
- 通过对DYRK1B或STAT3进行向,可以通过使线粒体功能复苏来改善心脏功能.
相关概念视频
Cardiomyopathy III: Hypertrophic Cardiomyopathy
78
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
78
Heart Failure II: Pathophysiology
85
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
85
Cardiomyopathy II: Dilated Cardiomyopathy
47
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47
PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K
Heart Failure I: Introduction
98
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
98
Cardiomyopathy IV: Restrictive Cardiomyopathy
77
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
77


